Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir Zeb has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Phytochemicals at the PPAR–NF‐ κ B Interface: A Structured Narrative Review of Receptor Pharmacology, Inflammatory Signaling, and Translational Barriers

    by Sabi Ur Rehman, Fazal Ur Rehman, Shafi Ullah Khan, Amir Zeb, Saleha Ashfaq, Waheed Ullah Hafiz

    Background: The peroxisome proliferator‐activated receptors (PPARs) and nuclear factor‐ κ B (NF‐ κ B) signaling axis serves as master molecular interface governing metabolic homeostasis and inflammatory resolution. Dysregulated reciprocal repression between PPAR‐ α / γ and NF‐ κ B contributes to chronic inflammatory diseases, metabolic syndrome, and malignancy. Synthetic full agonists (e.g., thiazolidinediones and fibrates) are associated with clinical liabilities including adipogenesis, fluid retention, hepatotoxicity, and cardiovascular adverse effects, underscoring the need for safer modulators. Objective and Rationale: This structured narrative review provides a rigorous mechanistic synthesis of plant derived phytochemicals with selective PPAR modulator (SPPARM) like pharmacology. We elucidate how distinct chemical classes may achieve targeted NF‐ κ B transrepression with reduced transcriptional liability, summarize available ligand receptor binding data, and critically evaluate translational hurdles. Methods: A structured narrative review was conducted using a systematic style literature search across PubMed/MEDLINE, Scopus, and Web of Science from January 2000 through March 2026. In line with PRISMA 2020 principles for transparent reporting, original research articles were prioritized according to evidence type (clinical, preclinical, in vivo, and in vitro/in silico), with emphasis on pharmacodynamic metrics, binding kinetics (K i , EC 50 , and IC 50 ), receptor dependency validation (knockout, antagonism), and pharmacokinetic data. Results: Chemically diverse phytochemicals including flavonoids, neolignans, stilbenoids and terpenoids exhibit partial or subtype selective PPAR agonism in reporter and binding assays. Mechanistically, many favor anti‐inflammatory transrepression over full coactivator‐dependent transactivation, with evidence for corepressor recruitment and inhibition of NF‐ κ B nuclear translocation in selected models. However, integrated analysis reveals a persistent disconnect between submicromolar in vitro potency and negligible systemic exposure of free parent compound (low C max , extensive glucuronidation/sulfation), compounded by frequent reliance on unvalidated docking simulations and PPAR‐independent NF‐ κ B inhibition. Conclusion: Phytochemicals with SPPARM‐like pharmacology represent a promising but unvalidated paradigm for nonsteroidal inflammation control. Realizing their potential will require next‐generation delivery systems (e.g., liposomes, nanoemulsions, and cyclodextrin complexes), mandatory genetic or pharmacological receptor validation, and biomarker‐driven clinical trials that document target engagement at achievable human exposure levels.

  • Deciphering Puerarin’s Therapeutic Potential Against LPS-Induced Nephrotoxicity: A Computational and Animal Model Study

    by Haris Faraz, Ashraf Ullah Khan, Bushra Rehman, Aman Ullah, Salman Khan, Amir Zeb, Mohamed Alshehri, Dalal Sulaiman Alshaya, Eman Fayad, Amin Ullah

    The current project aimed to determine the protective effect of Puerarin against lipopolysaccharide (LPS)-induced renal injury using animal and computational models. The LPS is the integral component of the outer layer of gram-negative bacteria and is associated with multiple organ damage, including the kidney. The animals were pre-treated with the drugs, and following pre-treatment, the animals were administered LPS intraperitoneally (IP). The LPS administration showed a higher mortality rate, i.e., 45%. The Puerarin-treated groups showed marked protection against the LPS-induced mortality compared to the LPS-treated group. The Puerarin administration showed marked improvement in the body temperature, and the wet-to-dry ratio was reduced significantly as compared to only the LPS-treated group. The in vivo activity was followed by the computational studies using docking, molecular dynamics simulation, and binding free energy calculations. The molecular docking of Puerarin was performed against the 3GQL, TGF-B, STAT, SMAD2, and JAK to assess the binding affinity. Following the molecular docking, the MD simulation was performed for 50 ns, and the results showed dynamic stability of the complexes. After the MD simulation, the binding free energy was calculated to validate the results of the molecular docking and MD simulation. In conclusion, Puerarin showed significant activity against LPS-induced renal injury using both in vivoand computational studies; however, further studies will be required to employ Puerarin for the clinical treatment of renal injury.

  • Synthesis and Evaluation of Anti-Inflammatory and Anti-Nociceptive Potential of Novel Acyl Hydrazone Derivatives of Ketoprofen using DFT, Virtual Screening, MD Simulation and Binding Free Energy Calculations

    by Muhammad Zubair, Muhammad Waqar, Ashraf Ullah Khan, Aishma Khattak, Nadia Bibi, Kaleem Ullah, Amir Zeb, Amin Ullah, Mumtaz Ali

    In this study, the ketoprofen derivatives were evaluated against inflammation and nociception using comprehensive computational methods. These derivatives were synthesized by modifying the structure of ketoprofen, a well-known NSAID (nonsteroidal anti-inflammatory drug) used clinically for the management of pain and inflammation. The virtual screening was performed to predict the binding affinities of the ketoprofen-based acyl hydrazone derivatives with key inflammatory and pain-related targets including cyclooxygenase-2 (COX-2), Transient Receptor Potential menthol-8 (TRPV1), c-Jun N-terminal Kinase-3 (JNK3), Extracellular Receptor Kinase (ERK) and Purinergic Receptor Type Y1 (P2Y1) to obtain the top hits. The virtual screening studies revealed the top hits such as COMP2, COMP10, COMP16 and COMP17 against the target protein. Based on the virtual screening, Molecular Dynamic (MD) simulation was performed on the top hits for 50 ns by using parameters like Root Mean Square Fluctuations (RMSF), Root Mean Square Deviation (RMSD), Radius of Gyration (RoG), Solvent Accessible Surface Area (SASA) and hydrogen bonds. The three complexes showed significantly lowered RMSD value and hence, the complexes remained stable throughout the simulation. For binding free energy, Molecular, Mechanics-Poison Boltzmann Surface Area (MM-PBSA) and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) were performed after MD simulation for the analysis of stability in the context of energy. The MM-PBSA and MM-GBSA evaluation showed overall energy of the system remains negative and indicates favorable binding interaction and hence, stability of the complexes. Furthermore, the per-residue decomposition was carried out to evaluate each amino acid involved in the ligand-protein interaction, and highest contributing amino acid in terms of energy involved in the ligand-protein interactions. The binding free energy calculation was succeeded by Density Functional Theory (DFT) analysis to evaluate the Highest Occupied Molecular Orbital (HOMO), Lowest Unoccupied Molecular Orbital (LUMO) and the HOMO-LUMO gap. In conclusion, the four compounds showed significant activity against pain and inflammation based on the computational analysis; however, to employ it clinically further analysis will be required.


  • Open Access

    Bergamottin and PAP-1 Induced ACE2 Degradation to Alleviate Infection of SARS-CoV-2

    by Mengjia Li, Yongzheng Zhang, Amir Zeb, Yang Wu, Lufeng Cheng

    Angiotensin-converting enzyme 2 (ACE2), a functional receptor for SARS-CoV, now appears likely to mediate 2019-nCoV entry into human cells. However, inhibitors such as PAP-1 and bergamottin have been discovered; both of them can preferentially bind to ACE2, prevent RBD Spike S protein from binding to ACE2, and reduce the binding sites for RBD Spike S protein. In addition, we investigated the binding energy of PAP-1 and bergamottin with ACE2 through molecular docking with bio-layer interferometry (BLI) and found relatively high binding affinity (KD = 48.5 nM, 53.1 nM) between the PAP-1 and bergamottin groups. In addition, the nanomolar fraction had no effect on growth of the AT-II cell, but 150 µM PAP-1 and 75 µM bergamottin inhibited the proliferation of AT-II cells in vitro by 75% and 68%, respectively. Meanwhile, they significantly reduced ACE2 mRNA and proteins by 67%, 58% and 55%, 41%, respectively. These results indicate that psoralen compounds PAP-1 and bergamottin binding to ACE2 protein could be further developed in the fight against COVID-19 infection during the current pandemic. However, attention should be paid to the damage to human alveolar type II epithelial cells.